公开(公告)号：US20200181643A1

公开(公告)日：2020-06-11

申请号：US16793918

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  C12N5/0783 ,  C12N15/90 ,  C12N9/22 ,  A61K35/17

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20190338015A1

公开(公告)日：2019-11-07

申请号：US16342139

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Laurent POIROT ,  Murielle DERRIEN ,  Donna Marie STONE ,  Javier Fernando CHAPARRO RIGGERS

IPC: C07K14/705 ,  C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28

Abstract: The invention relates to cell death inducing chimeric antigen receptors (D-CAR). In particular, the present invention relates to cell death inducing chimeric antigen receptors which comprise at least one death domain in their endodomain, including cell death inducing chimeric antigen receptors comprising within their death domains modifications which attenuate the self-association and/or binding to pro-apoptotic or pro-necrotic adaptor proteins, such as FADD or TRADD. Moreover, the present invention relates to an engineered immune cell expressing at its surface a cell death inducing CAR of the present invention and, optionally, an activating chimeric antigen receptor, wherein the extracellular ligand-binding domains of the cell death inducing CAR and the activating CAR bind to different antigens. The engineered immune cell may furthermore comprise at least one edited (e.g., inactivated) gene selected from TCR genes, immune check point genes, genes involved in drug resistance, and combinations thereof.

公开(公告)号：US20190328783A1

公开(公告)日：2019-10-31

申请号：US16092414

申请日：2017-04-13

Applicant: CELLECTIS

Inventor： Julien VALTON ,  Philippe DUCHATEAU ,  Laurent POIROT ,  Barbra Johnsson SASU ,  Arvind RAJPAL

IPC: A61K35/17 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85

Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering prodrug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific prodrug in case of occurrence of a serious adverse event. The invention opens the way to safer and tunable adoptive immunotherapy strategies for treating cancer.

公开(公告)号：US20190151478A1

公开(公告)日：2019-05-23

申请号：US16092417

申请日：2017-04-13

Applicant: CELLECTIS

Inventor： Julien VALTON ,  Veronique ZENNOU ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC: A61K48/00 ,  A61P35/00 ,  A61P31/00

Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.

公开(公告)号：US20180327761A1

公开(公告)日：2018-11-15

申请号：US16045602

申请日：2018-07-25

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  Claudia BERTONATI

IPC: C12N15/82 ,  C12N15/90 ,  C12N15/10 ,  C12Q1/683

CPC classification number: C12N15/8213 ,  C12N15/10 ,  C12N15/907 ,  C12Q1/683 ,  C12Q2521/307

Abstract: The present invention is in the field of a method for genome engineering based on the type II CRISPR system, particularly a method for improving specificity and reducing potential off-site. The method is based on the use of nickase architectures of Cas9 and single or multiple crRNA(s) harboring two different targets lowering the risk of producing off-site cleavage. The present invention also relates to polypeptides, polynucleotides, vectors, compositions, therapeutic applications related to the method described here.

公开(公告)号：US20180291343A1

公开(公告)日：2018-10-11

申请号：US15556558

申请日：2016-03-11

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  Jean-Pierre CABANIOLS ,  Julien VALTON ,  Laurent POIROT

IPC: C12N5/0783 ,  C07K16/28 ,  C07K14/705 ,  C12N15/11 ,  C12N9/22 ,  C07K14/74 ,  C07K14/005 ,  A61K35/17 ,  C12N5/00

Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.

公开(公告)号：US20180000914A1

公开(公告)日：2018-01-04

申请号：US15546604

申请日：2016-01-25

Applicant: Cellectis

Inventor： Julien VALTON ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Arvind RAJPAL ,  Barbra Johnson SASU ,  Julianne SMITH

IPC: A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C07K14/735 ,  A61K39/395 ,  C07K16/28 ,  C07K14/705

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an anti-HSP70 monoclonal antibody, conferring specific immunity against HSP70 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating in particular leukemia.

公开(公告)号：US20160273003A1

公开(公告)日：2016-09-22

申请号：US15080232

申请日：2016-03-24

Applicant: Cellectis S.A.

Inventor： Philippe DUCHATEAU ,  Christophe PEREZ ,  Sylvia BRUNEAU ,  Jean-Pierre CABANIOLS ,  Julianne SMITH ,  Agnes GOUBLE

IPC: C12N15/90 ,  C07K14/435 ,  C12N15/86 ,  C12N9/22 ,  A61K38/46 ,  C12N7/00

CPC classification number: C12N15/907 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0337 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/465 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/435 ,  C07K2319/81 ,  C12N7/00 ,  C12N9/22 ,  C12N15/1058 ,  C12N15/8509 ,  C12N15/86 ,  C12N15/90 ,  C12N2730/10143 ,  C12N2799/022 ,  C12N2800/80 ,  C12N2830/002 ,  C12N2830/55 ,  C12N2840/20 ,  C12N2840/44 ,  C12Y301/00 ,  C12Y301/21004

Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.

Abstract translation: 单链归巢内切核酸酶，其包含具有登录号pdb 1g9y的氨基酸序列的I-CreI的第一变体和在单个多肽中具有登录号pdb 1g9y的氨基酸序列的I-CreI变体的第二变体。

公开(公告)号：US20250002945A1

公开(公告)日：2025-01-02

申请号：US18712640

申请日：2022-11-23

Applicant: CELLECTIS SA

Inventor： Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Alex BOYNE ,  Selena KAZANCIOGLU

IPC: C12N15/90 ,  C07K14/195 ,  C12N9/22

Abstract: The present invention relates to the design of improved TALE protein fusions useful as sequence-specific genomic reagents, such as TALE-nucleases and TALE base editors, displaying higher on-target/off-target activity ratios. Its goal is to produce safer reagents to genetically modify the genomes of different types of cells, especially mammalian cells, in particular for their use in gene therapy.

公开(公告)号：US20230279440A1

公开(公告)日：2023-09-07

申请号：US17996701

申请日：2021-05-06

Applicant: CELLECTIS S.A.

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Patrick HONG ,  Laurent POIROT ,  Brian BUSSER ,  Alex BOYNE

IPC: C12N15/90 ,  C12N15/86

CPC classification number: C12N15/907 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2830/42

Abstract: The present disclosure provides methods to genetically modify cells by insertion of an artificial exon (ArtEx) for delivery of therapeutic proteins in specific cell types and more particularly engineered cells for expression of a transgene into the brain of a patient.